Fejer Varmegyei Szent Gyoergy Egyetemi Oktato Korhaz
- Address
- lock Available on a paid plan
Fejer Varmegyei Szent Gyoergy Egyetemi Oktato Korhaz - Comprehensive Clinical Research Center
Fejer Varmegyei Szent Gyoergy Egyetemi Oktato Korhaz is a leading Hungarian university teaching hospital with extensive expertise in multi-specialty clinical research. The center demonstrates particular strength in oncology, cardiovascular medicine, inflammatory bowel diseases, and rheumatology, conducting numerous Phase 2 and Phase 3 trials across diverse therapeutic areas.
- Advanced Non-Small Cell Lung Cancer research, including investigations of novel immunotherapies, targeted therapies, and combination regimens for various NSCLC subtypes with EGFR mutations, HER2 alterations, and PD-L1 expression
- Inflammatory Bowel Disease studies focusing on Crohn's disease and ulcerative colitis, evaluating both novel biologics and small molecule therapies for moderately to severely active disease
- Cardiovascular and hematological conditions, including atrial fibrillation, chronic heart failure, acute coronary syndromes, and lipid disorders such as severe hypertriglyceridemia and elevated lipoprotein(a)
- Rheumatological disorders with particular emphasis on psoriatic arthritis and axial spondyloarthritis, testing both biologic-naïve and biologic-experienced patient populations
The center's research portfolio extends to hematologic malignancies including chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and myelofibrosis, as well as surgical infection prevention, chronic hepatitis B, and respiratory conditions such as ARDS and chronic rhinosinusitis with nasal polyps. With participation in global trials of cutting-edge therapies including bispecific antibodies, novel immunotherapies, and targeted oral agents, the hospital serves as a vital contributor to international clinical research advancement.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 12 therapeutic areas and 15 of 138 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 124 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 23 by active trials.
- 1AstraZeneca AB6active
lock +22 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB12trials
lock +15 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fejer Varmegyei Szent Gyoergy Egyetemi Oktato Korhaz
lock Showing 1 of 80 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 138 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 14 | Unknown | 2018-08-24 | 2025-07-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.